FDA Approves Talecris's Neurologic Drug
Posted on: Monday, 15 September 2008, 09:00 CDT
The FDA has approved Talecris Biotherapeutics's Gamunex, an immune globulin product for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.
The FDA designated Gamunex as an orphan drug to treat chronic inflammatory demyelinating polyneuropathy (CIDP). The FDA based its approval of Gamunex on clinical trials that showed Gamunex was effective at improving certain motor functions for up to 48 weeks after the initial treatment. Researchers used the inflammatory neuropathy cause and treatment scale (INCAT) to measure a patient's ability to perform tasks such as walking and motor tasks for the hands.
The trials showed improved CIDP patient INCAT scores for muscle function after receiving Gamunex every three weeks for a 24-week period. Approximately 28 of 59 patients treated with Gamunex had improved INCAT scores compared to 13 of 58 patients treated with placebo.
In addition, patients with improved INCAT scores participated in a follow-up trial for an additional 24 weeks. Approximately 86% of the patients who continued to receive Gamunex maintained their improved INCAT scores compared to 61% of the patients who received placebo during the follow-up trial.
Gamunex is manufactured by Talecris Biotherapeutics of Research Triangle Park, North Carolina.
Jesse Goodman, director of the FDA's Center for Biologics Evaluation and Research, said: "This approval is part of the FDA's effort to address unmet medical needs in patients who are suffering from rare and serious diseases."
Source: Datamonitor
Related Articles
- Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
- IDF Applauds Legislation to Improve Patient Access to Life-Saving IVIG Treatment
- Patient-Reported Outcomes (PROs) Improve Cancer Treatment -- Experts Agree
- Chronic Low Back Pain is Reduced, Analgesic Use is Reduced, and Activities of Daily Living Improved Following Treatment With the DRX9000(TM).
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Genomic Health, Inc. Announces Oncotype DX(TM) Recurrence Score(TM) Influences Treatment Decisions for Physicians and Patients in Prospective Study
- Seventy-Eight Percent of Newly Diagnosed Dyslipidemia Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- FDA Approves MIRAPEX for the Treatment of Moderate-to-Severe Primary Restless Legs Syndrome
- FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
- Baker Schools Test Scores Improve
User Comments (1)
| 1. |
Posted by Theo Wagner on 09/16/2008, 11:54 Very poor and misleading terminology and reporting of the recent added indication for Talecris' Gamunex for treatment of CIDP. "Throw Mother from the train, a kiss?". "An immune globulin product for the treatment of CIDP". Gamunex is not a "drug" but a biologic and has been FDA licensed as a replacement therapies for the treatment of immune deficiency and ITP. Gamunex and its competing IVIg products have been continually utilized for the treatment of CIDP for over 20 years and supported by numerous peer-reviewed articles in medical journals. However, Gamunex has clearly been the FIRST IVIg to receive FDA licensure for temporary and not chronic treatment of this demyelinating disorder. |
RSS Feeds